Vaxcyte COO Jim Wassil sells $689,790 in stock

In recent transactions reported to the Securities and Exchange Commission, Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine company with a market capitalization of $10.8 billion, executed a series of stock sales amounting to approximately $689,790. The sales occurred on February 3, 2025, with shares sold at prices ranging from $85.996 to $87.94 per share, close to the current trading price of $86.52. These transactions were part of a Rule 10b5-1 trading plan adopted on March 1, 2024. According to InvestingPro, the company maintains strong liquidity with a current ratio of 17.88.

In addition to the stock sales, Wassil also exercised options to acquire 8,000 shares at a price of $2.42 per share, totaling $19,360. Following these transactions, Wassil holds 205,695 shares of Vaxcyte common stock. While the company is not yet profitable, with earnings per share at -$4.46, InvestingPro analysis reveals several additional key insights about the company’s financial health and growth prospects.

In other recent news, Vaxcyte has been making significant strides in the biotechnology sector. Goldman Sachs initiated coverage on Vaxcyte, highlighting the company’s strong clinical data for its lead programs, and anticipating significant catalysts such as the upcoming data for VAX-24 in the infant/pediatric population expected in the first quarter of 2025. Additionally, Jefferies has increased the price target for Vaxcyte, following positive developments in the company’s vaccine program, particularly the progress with VAX-31. Leerink Partners also reiterated its Outperform rating on Vaxcyte, noting the company’s promising pipeline developments.

Further, Vaxcyte has expanded its corporate headquarters in San Carlos, California, reflecting the company’s growth and ongoing commitment to its operations and research. The company has also subleased a portion of its space to Iovance Biotherapeutics (NASDAQ:IOVA), Inc.

On the regulatory front, the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VAX-31 in infants and granted Breakthrough Therapy designation for its use in adults. This follows positive results from earlier Phase 1/2 studies.

These are recent developments that underline Vaxcyte’s commitment to addressing next-gen vaccine challenges and its potential for significant global commercial opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.